William G. Kaelin, Jr., MD
2019 Nobel Prize Recipient
Professor, Department of Medical Oncology, Dana-Farber
Professor of Medicine, Harvard Medical School
A new assay for the identification of novel protein targets that control protein stability and chemicals that destabilize proteins of interest.
Dr. William Kaelin’s lab has developed a novel “up” screening assay for identifying chemical or genetic perturbants that can destabilize a protein of interest.
This assay uses, for example, cell survival and/or cell viability as a phenotypic identifier to positively select for destabilizing agents. For example, cells expressing fusion constructs having an enzyme, which converts an exogenous substrate that is not cytotoxic into a product that is fused to a POI may be cultured in the presence of a test agent. If the test agent destabilizes the POI, a corresponding decrease in the cytotoxic element fused to the POI promotes cell survival and/or viability. In this assay, for example, a protein of interest can be fused to a modified deoxycytidine kinase (dCK) gene capable of converting bromovinyldeoxyuridine (BVdU) to a toxic metabolite.
This method provides a powerful new way of identifying protein destabilizing agents as it provides enhanced sensitivity including better signal-to-noise ratio and fewer false positives compared to prior assays, while enabling performance in pooled, arrayed, multi-well, high-throughput formats.
Further details:
Koduri V, Duplaquet L, et al. Targeting oncoproteins with a positive selection assay for protein degraders. Science Advances. 2021 Feb; 7(6): eabd6263.
Identification of novel protein targets that control protein stability and chemicals that destabilize proteins of interests.
2019 Nobel Prize Recipient
Professor, Department of Medical Oncology, Dana-Farber
Professor of Medicine, Harvard Medical School
Oncologist and Scientist, Division of Hematology, Brigham and Women’s Hospital